TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8230517
Drug: Estramustine (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine (560 to 700 mg orally per day)
Study: 8230517
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (15 mg/m2 by intravenous infusion every 6 weeks)
Study: 3541419
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate slow release 120 mg once a day
Study: 24983446
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (MTX) administration via prefilled autoinjector pen
Study: 24983446
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) administration
Study: 16268802
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 60 mg
Study: 22703757
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 90 mg
Study: 10769580
Drug: Combined supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplements of several antioxidant vitamins
Study: 9333111
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day for 4 days
Study: 8403714
Drug: Standard feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard feeding (commercial milkshake taken immediately after injection)
Study: 8403714
Drug: Feeding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding of lipid after injection
Study: 3780286
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol plus 12.5 mg hydrochlorothiazide twice daily
Study: 3780286
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol plus 25 mg hydrochlorothiazide once daily
Study: 30369162
Drug: NSAID injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID injection
Study: 24603353
Drug: AM-101 0.81
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-101 0.81 mg/ml
Study: 24603353
Drug: AM-101 0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-101 0.27 mg/ml
Study: 20466440
Drug: PI-2301 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (3 mg)
Study: 20466440
Drug: PI-2301 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (10 mg)
Study: 20466440
Drug: PI-2301 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-2301 (1 mg)
Study: 17678567
Drug: Fish oil/evening
Normalized name: omega-3/dha/epa/fish oil/evening primrose oil 58 mg-84 mg-291 mg-140 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil/evening primrose oil (FSO/EPO) blend (456 mg DHA/d and 353 mg GLA/d)
Study: 15972565
Drug: No offer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No offer of antibiotics
Study: 1856148
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing regimen
Study: 1856148
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing regimen
Study: 6136101
Drug: Lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide tromethamine 0.01 mg
Study: 6136101
Drug: Lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide tromethamine 0.1 mg
Study: 10425980
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (100 mg)
Study: 23021528
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine hydrochloride with 1:100,000 epinephrine
Study: 19898218
Drug: PegIntron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIntron (all doses)
Study: 17325604
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Gag/Pol DNA vaccine
Study: 17325604
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg Gag/Pol DNA vaccine
Study: 17325604
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg Gag/Pol DNA vaccine
Study: 17325604
Drug: Gag/Pol DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gag/Pol DNA vaccine (all doses)
Study: 12973849
Drug: 8-drugs-in-1-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8-drugs-in-1-day regimen
Study: 10374248
Drug: Banxia Houpo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banxia Houpo Tang (BHT) 7.5 g per day for four weeks
Study: 8678102
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g thrice daily)
Study: 8678102
Drug: Comparator regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator regimens (ceftazidime 2 g thrice daily or piperacillin + gentamicin 3 g every 4 hours + 1.5 mg/kg every 8 hours)
Study: 7082781
Drug: Tablet dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet dosage forms (three different tablet products)
Study: 7082781
Drug: Reference solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference solution
Study: 19663099
Drug: zhinbiticose (western
Approvals — FDA: no, EMA: no, PMDA: no
Description: zhinbiticose (western medicine)
Study: 16085252
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg loading dose intrarectally, followed by 650 mg every 4 hours for 48 hours)
Study: 16085252
Drug: Placebo (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (loading dose and subsequent doses as a placebo suppository)
Study: 10702890
Drug: cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol 100 mg twice daily for 13 days
Study: 10702890
Drug: placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily for 13 days
Study: 30466484
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (national smoking cessation help line)
Study: 22226430
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of PDT and imiquimod
Study: 17875242
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) 150-600 mg/d
Study: 17875242
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 900-3600 mg/d
Study: 11836333
Drug: 17beta-estradiol (E2)
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol (E2) 1 mg orally twice daily
Study: 7628023
Drug: Systematic i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic i.m. morphine regimen calculated from the initial titrated dose
Study: 7628023
Drug: Initial i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial i.v. morphine dose < or = 6 mg followed by paracetamol only
Study: 7628023
Drug: High-dose or
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose or low-dose i.m. morphine regimen
Study: 8238144
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of aspirin daily
Study: 21744200
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection
Study: 23063945
Drug: Nefopam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (0.3 mg/kg bolus at induction followed by 0.065 mg/kg/h for 48 hours)
Study: 23063945
Drug: Nefopam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (0.3 mg/kg bolus at end of surgery followed by 0.065 mg/kg/h for 48 hours)
Study: 19178788
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (9 mg caffeine)
Study: 11837985
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (1 g daily)
Study: 11837985
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg daily)
Study: 9624885
Drug: Combined calcium
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined calcium and vitamin D supplementation (500 mg calcium and 700 IU vitamin D daily for 3 years)
Study: 8048325
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment timeliness by seamen
Study: 3292597
Drug: Cetamolol 5-10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetamolol 5-10-15 mg/d (low dose)
Study: 3292597
Drug: Cetamolol 15-25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetamolol 15-25-50 mg/d (high dose)
Study: 3292597
Drug: Cetamolol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetamolol (both doses)
Study: 29478187
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng (AG) extract 1 g/meal (3 g/day) for 8 weeks
Study: 28648948
Drug: Prophylactic Cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Cranial Irradiation plus Consolidative Radiation Therapy (PCI+cRT)
Study: 20972950
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment without ECT
Study: 16443517
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with cyclophosphamide, cisplatin, and carmustine followed by autologous hematopoietic support
Study: 16443517
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (observation arm)
Study: 16443517
Drug: Salvage high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage high-dose chemotherapy (HDC) after partial response to AFM
Study: 14518596
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg/day plus Clodronate (CLD) 100 mg i.m. every 10 days
Study: 1530798
Drug: Fadrozole 1
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 1 mg/d
Study: 1530798
Drug: Fadrozole 4
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 4 mg/d
Study: 1530798
Drug: Fadrozole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole (both doses)
Study: 6383127
Drug: Buflomedil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil (600 mg daily)
Study: 31254849
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 60 l/min
Study: 30282685
Drug: bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bovine lactoferrin (bLF) added to feeds (up to 250 mg/kg/day)
Study: 17987126
Drug: Flaxseed-derived lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed-derived lignan capsules (360 mg lignan per day)
Study: 17987126
Drug: Flaxseed-derived lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed-derived lignan capsules
Study: 15220366
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care patients on atorvastatin (n=783)
Study: 12365090
Drug: Telmisartan (T)
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan (T) 40 mg once daily
Study: 12365090
Drug: Perindopril (P)
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril (P) 4 mg once daily
Study: 7866482
Drug: Tetrahydroaminoacridine (THA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA, tacrine) treatment for 1 year
Study: 2527537
Drug: Cilazaprilat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazaprilat (2 mg intravenous infusion)
Study: 26787687
Drug: Surotomycin 250
Normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surotomycin 250 mg twice daily for 14 days
Study: 26787687
Drug: Surotomycin 500
Normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surotomycin 500 mg twice daily for 14 days
Study: 26787687
Drug: Surotomycin 1000
Normalized name: streptomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surotomycin 1000 mg twice daily for 14 days
Study: 25176098
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.5 mg bevacizumab
Study: 25176098
Drug: Non-intravitreal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intravitreal treatment (only vitreous operation and membrane peeling)
Study: 18674471
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d atorvastatin
Study: 22135385
Drug: 20-40 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-40 mg/d simvastatin
Study: 20560292
Drug: Pentoxifylline (1200-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200-2000 mg/day)
Study: 10447227
Drug: Clodronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (400 mg capsules twice a day for 2 years)
Study: 24988203
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional therapy)
Study: 7499633
Drug: Questionnaire administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnaire administered before physician or family nurse practitioner visit
Study: 1948517
Drug: Ceftizoxime 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 250 mg IM
Study: 2264006
Drug: Ceftizoxime 500
Normalized name: ceftizoxime 500 mg injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 500 mg IM
Study: 30764648
Drug: CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT plus medication (escitalopram)
Study: 30764648
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus CBT (CBT added after antidepressant)
Study: 30764648
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CBT plus medication or medication plus CBT)
Study: 30764648
Drug: CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT plus medication and Medication plus CBT
Study: 25993594
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg/day) plus standard ADHF therapy
Study: 25993594
Drug: Standard ADHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ADHF therapy alone (Control)
Study: 22146614
Drug: Alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 20 μg kg(‐1)
Study: 17985810
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg citrus flavonoids plus 30 mg tocotrienols (S)
Study: 15848148
Drug: Perception of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perception of oral dryness ratings using Visual Analog Scales.
Study: 15848148
Drug: Perception of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perception of oral wetness in low and very low UWSFR groups at 11:30 a.m.
Study: 14511846
Drug: Lercanidipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 5 mg
Study: 9869018
Drug: Lercanidipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 2.5 mg
Study: 9869018
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg (24 h ambulatory)
Study: 9869018
Drug: Lercanidipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 2.5 mg (24 h ambulatory)
Study: 9869018
Drug: Lercanidipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 5 mg (24 h ambulatory)
Study: 9869018
Drug: Smoothness index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoothness index for 2.5 mg lercanidipine
Study: 9869018
Drug: Smoothness index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoothness index for 5 mg lercanidipine
Study: 9869018
Drug: Smoothness index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoothness index for 10 mg lercanidipine
Study: 2223155
Drug: Bestatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin treatment in invasive treatment group
Study: 2223155
Drug: Bestatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin treatment in non-invasive treatment group
Study: 2223155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in invasive treatment
Study: 2223155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in non-invasive treatment
Study: 31919773
Drug: Aflibercept monotherapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept monotherapy (group B)
Study: 26348542
Drug: Camicinal (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal (125 mg)
Study: 23464844
Drug: Ciprofloxacin-resistant Gram-negative
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin-resistant Gram-negative coliforms identified in rectal flora
Study: 21183734
Drug: INV-403 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: INV-403 (20 mg/kg per day)
Study: 11020741
Drug: CP‐122,721 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐122,721 200 mg
Study: 11020741
Drug: CP‐122,721 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐122,721 100 mg
Study: 11020741
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CP‐122,721 200 mg + ondansetron 4 mg)
Study: 1739372
Drug: MDC (multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDC (multiple-dose charcoal)
Study: 6386031
Drug: Superficial X-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial X-ray therapy (100 rad at 50 kV on three occasions at intervals of 21 days)
Study: 6386031
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control hand)
Study: 23609584
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling therapy
Study: 28158152
Drug: Cross tape
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross tape therapy
Study: 25187003
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation (CS) - 10 twice weekly meetings focused on a specific cognitive area.
Study: 24083759
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant EGF-based cream
Study: 21150465
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m, administered every 3 weeks)
Study: 21150465
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m, administered every 3 weeks)
Study: 18304284
Drug: Transdermal E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/NETA (50 microg/140 microg)
Study: 16444068
Drug: Gonadotrophin releasing
Normalized name: Gonadotrophin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin releasing hormone agonists (GnRH agonists)
Study: 15041351
Drug: CsA microemulsification
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA microemulsification formulation (CsA‐ME)
Study: 8507027
Drug: 0.05% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% NaF rinse used once daily
Study: 8507027
Drug: 0.4% SnF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% SnF2 gel applied twice daily
Study: 8507027
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 0.05% NaF rinse and 0.4% SnF2 gel
Study: 25335123
Drug: High-dose Epoetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Epoetin beta (30,000 IU on days 1, 2, and 3)
Study: 25335123
Drug: Low-dose Epoetin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11, and 13)
Study: 23532835
Drug: Existential behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existential behavioural therapy (EBT)
Study: 20006168
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (300 microg)
Study: 20006168
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion (fresh frozen plasma 10 mL/kg and/or 1 unit of single donor platelets)
Study: 16632019
Drug: Oral fludrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludrocortisone (0.1 mg/d; n = 18)
Study: 16632019
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control; n = 19)
Study: 12955758
Drug: Static magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static magnetic field (SMF) combined with antineoplastic chemotherapy
Study: 10998482
Drug: LDL-apheresis (LA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis (LA) with concomitant simvastatin administration
Study: 30153382
Drug: Levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium oral solution (4 × 150-μg unit-dose ampules) with water
Study: 30153382
Drug: Levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium oral solution (4 × 150-μg unit-dose ampules) without water